Global Charities Join Forces to Drive Forward New Drug for Parkinson's
November 24, 2020
November 24, 2020
NEW YORK, Nov. 24 -- The Michael J. Fox Foundation for Parkinson's Research issued the following news release:
Leading charities Parkinson's UK and The Michael J. Fox Foundation for Parkinson's Research have joined forces to fund a pound sterling1.5 million ($2 million) phase 2 clinical trial investigating the effects of a new drug called NLX-112 with biopharmaceutical company Neurolixis. This drug has shown potential in the lab for reducing dyskinesia -- a common side effect of cur . . .
Leading charities Parkinson's UK and The Michael J. Fox Foundation for Parkinson's Research have joined forces to fund a pound sterling1.5 million ($2 million) phase 2 clinical trial investigating the effects of a new drug called NLX-112 with biopharmaceutical company Neurolixis. This drug has shown potential in the lab for reducing dyskinesia -- a common side effect of cur . . .